ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ADMA
RXRX (40) BEAM (33) BCRX (67) DNLI (35) ⌘ Pro Terminal →

ADMA Biologics Inc (ADMA) — RQD Stock Rating Cockpit

$11.06 -3.07% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.98

ADMA Biologics Inc (ADMA) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $2.56B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ADMA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ADMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, ADMA Biologics Inc (NASDAQ: ADMA) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $11.06 (-3.07% 1D, market cap $2.56B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, ADMA ranks #83 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ADMA compare to RXRX and BEAM in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ADMA carries a Roarable C+ (69/100 RQD), trailing P/E of 17.9x, gross margin of 57.4%, and ROIC of 32.9%. By comparison, RXRX (Recursion Pharmaceuticals Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $2.41B) and BEAM (Beam Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -32.1%, cap $2.81B). Among the 5-stock peer group, BCRX leads on earnings multiple (8.3x) while BCRX leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ADMA?
▼

Per ADMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001368514), ADMA Biologics Inc generated $510.2M in revenue (+19.6% YoY), $146.9M in net income, and $27.8M in free cash flow against $624.2M in total assets and $69.3M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $10.98 (-0.74%)🧬 Cannibal Buyback (-0.88% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 5.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY • 57.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C+
025507510069
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw C · Rk B
Cash (12)Whales (12)SEC (15)Macro (15)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+5% Base Target
$21 Bull$12 Base$9 Bear
📬 FREE ADMA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ADMA)Realized 20D OHLCV Swing Band: ±7.2%
Deterministic 5-Pillar Attribution (69/100 Composite)
🔍 WHY ADMA SCORES 69/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+15/20 pts (22% of score)

Altman Z-Score 12.98 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Macro Regime Fit+15/20 pts (22% of score)

FRED Regime × Technicals: 29% of 52W Range • RSI-14 at 60.9 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Whale & Options Positioning12/20 pts (-8 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-8 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
61
Grade C$10.31+8.9% Next Q
Q2 (-2Q)
64
Grade C+$11.23-0.5% Next Q
Q3 (-1Q)
66
Grade B-$11.17-1% Next Q
Current
69
Grade C+$11.06+2% Hist 90D α
Trajectory: C (61) → C+ (69)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ADMA Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 69/100 (C+) score, ADMA faces multiple-compression risk if 17.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-0.88% YoY Shares) — any gross margin slip below 54.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($10.07) or 200D SMA ($10.90) invalidates the momentum regime and cuts Target Base ($11.61) toward Bear Floor ($9.06).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ADMA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ADMA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 69%NO 31%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
60.930 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
12.98>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE29% OF RANGE
L: $7$11.06H: $20
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (57.4% gross margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C+RQD 27 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 30 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bullish on ADMA

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (60)

32.9% ROIC with 57.4% gross margin and 1.06% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (75)

Altman-Z 12.98 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (70)

27/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like ADMA
  • ✓Company leadership has skin in the game with net positive insider conviction.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (ADMA Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ADMA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +7.27%▲ ASCENDING CHANNEL
2026-11-03O $11.75H $11.75L $11.06C $11.06VOL 2.46M
RES: $11.95SUP: $9.05SMA50: $10.07SMA200: $10.90
$16.38$13.96$11.54$9.12$6.70RES $11.95SUP $9.05$11.062026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ADMA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ADMA Butterfly Map → + Track ADMA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
11.0%/yr Implied 5Y Growth

vs. +19.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ADMA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ADMA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ADMA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ADMA)

Health Care Rank #83 of 1015 ⚔️ RXRX vs ADMA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ADMA vs. RXRX, BEAM, BCRX, DNLI)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, ADMA Biologics Inc (ADMA) ranks #83 by composite RQD confidence (69/100, grade C+) and #217 by equity capitalization ($2.56B). Within this direct 5-issuer industry benchmark cohort, BCRX leads on earnings valuation at 8.3x trailing P/E, while BCRX leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. ADMA currently leads its immediate peer cohort in composite quantitative strength at 69/100 (C+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ADMA ACTIVE
ADMA Biologics Inc
C+ 69/100 17.9x 57.4% 32.9% -3.07% $2.56B Benchmark Subject
RXRX
Recursion Pharmaceuticals Inc.
D- 40/100 — 5.0% -35.0% -4.96% $2.41B /rxrx-vs-adma →
BEAM
Beam Therapeutics Inc.
E 33/100 — — -32.1% -4.99% $2.81B /beam-vs-adma →
BCRX
BioCryst Pharmaceuticals Inc.
C+ 67/100 8.3x — 85.0% -2.66% $2.16B /bcrx-vs-adma →
DNLI
Denali Therapeutics Inc.
D- 35/100 — — -35.0% -0.42% $3.03B /dnli-vs-adma →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001368514 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ADMA Biologics Inc (ADMA) reported GAAP revenue of $510.2M (+19.6% vs. FY2024 revenue of $426.5M , and +97.6% cumulative change since FY2023) , GAAP net income of $146.9M, operating cash flow of $50.4M, and free cash flow of $27.8M (-74.8% YoY). On the balance sheet, ADMA closed FY2025 with $624.2M in total assets against $69.3M in total debt (Altman Z-Score: 12.98, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $510.2M $146.9M $50.4M $27.8M $624.2M $69.3M
FY2024 (FY) 2024-12-31 $426.5M $197.7M $118.7M $110.4M $488.7M $72.3M
FY2023 (FY) 2023-12-31 $258.2M -$28.2M $8.8M $8.8M — —

3. ADMA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ADMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, ADMA Biologics Inc (NASDAQ: ADMA) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $11.06 (-3.07% 1D, market cap $2.56B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, ADMA ranks #83 in composite RQD confidence.

How does ADMA compare to RXRX and BEAM in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ADMA carries a Roarable C+ (69/100 RQD), trailing P/E of 17.9x, gross margin of 57.4%, and ROIC of 32.9%. By comparison, RXRX (Recursion Pharmaceuticals Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $2.41B) and BEAM (Beam Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -32.1%, cap $2.81B). Among the 5-stock peer group, BCRX leads on earnings multiple (8.3x) while BCRX leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ADMA?

Per ADMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001368514), ADMA Biologics Inc generated $510.2M in revenue (+19.6% YoY), $146.9M in net income, and $27.8M in free cash flow against $624.2M in total assets and $69.3M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ADMA trading relative to its 50-day, 200-day, and 52-week technical levels?

ADMA last traded at $11.06 (-3.07% on volume of 2,890,068 shares), positioning the stock +9.83% above its 50-day simple moving average ($10.07) and +1.47% above its 200-day simple moving average ($10.90). Across its 52-week range of $7.21 to $20.46, ADMA sits at the 29.1% percentile with a 14-day RSI of 60.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.2% ($10.26 to $11.86).

Direct Sub-Reports: ADMA RQD Cockpit ADMA 12M Forecast ADMA Earnings & Move ADMA Dividends & DRIP ADMA Insiders & 13F ADMA Whale Options ADMA Profit Sankey ADMA News & Why
ROARABLE RATING BRIEF • RQD 69/100 (C+) ✓ SEC XBRL & RQD VERIFIED

ADMA — ADMA Biologics Inc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

ADMA Biologics Inc (ADMA) earns a live Roarable RQD composite score of 69/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $11.06 (-3.07% 1D, market capitalization $2.56B).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of 32.9%, gross margin of 57.4%, operating margin of 37.5%, and free cash flow yield of 1.06%.
  • Whale 13F & Options Flow (12/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (15/20) + Forensic Balance Sheet (15/20): Incorporates a 1.00x equity beta, Altman Z-Score of 12.98, Piotroski F-Score of 7/9, and Debt/Equity of 0.15x.

2. Business Model, Unit Margins & SEC Financial Trajectory

ADMA Biologics Inc (ADMA) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. The company reported revenue of $510.2M for FY 2025, and per the market data it carries gross margin of 57.4%, operating margin of 37.5%, and net margin of 28.8%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), ADMA Biologics Inc (ADMA) reported $510.2M in annual revenue (up from $426.5M in FY2024, +19.6% YoY) and $146.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($258.2M revenue, -$28.2M net income) through FY2025, ADMA scaled operating cash flow to $50.4M and free cash flow to $27.8M, backed by $624.2M in total assets against $69.3M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C+ • RQD 69/100): Company leadership has skin in the game with net positive insider conviction. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $7.21 – $20.46 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 17.9x trailing P/E and 12.4x EV/EBITDA against 37.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Supply chain: NONE; butterfly links: none; proprietary signals: none. — for upstream and downstream dependency mapping, sector correlation coefficients, or 2nd-order bottleneck analysis. A prospective investor should note that the graph does not identify ADMA's suppliers, manufacturing inputs, or customers, so the ripple effects of any upstream disruption or downstream demand shift cannot be traced from the source material.

  • Key Question #1: Can ADMA sustain or expand its 37.5% operating margin and 32.9% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $510.2M and free cash flow of $27.8M, how will capital allocation balance growth reinvestment against $69.3M in total debt?
  • Key Question #3: How sensitive is ADMA's 15.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ADMA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ADMA Biologics Inc (ADMA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ADMA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ADMA Bull vs. Bear Conversation Board — What's Your Call at $11.06?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ADMA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ADMA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $14.60 (+28.0%)
📌 Pinned Debate

Operating income rose from $21.6M in FY 2023 to $191.4M in FY 2025 with a 32.9% ROIC and a 12.98 Altman Z-Score, indicating strong prof

Picked up a starter position in ADMA in my $100K Virtual Cash book at $11.41. Operating income rose from $21.6M in FY 2023 to $191.4M in FY 2025 with a 32.9% ROIC and a 12.98 Altman Z-Score, indicating strong profitability and balance sheet strength.. Trading inside a $7.21–$20.46 52-week range with 1.06% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

RetailWhale_TX 🐂 BULL

Both sides have a point here — ADMA's 15/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $9.70 (-15.0%)
Spot @ $11.41

Free cash flow fell from $110.4M in FY 2024 to $27.8M in FY 2025, and the 1.06% FCF yield is far below the 32.9% ROIC, suggesting earni

Fading this rally in ADMA at $11.41. Free cash flow fell from $110.4M in FY 2024 to $27.8M in FY 2025, and the 1.06% FCF yield is far below the 32.9% ROIC, suggesting earnings are not converting to cash.. With a beta of 1.0 and the stock sitting at $11.41 (52-wk range $7.21–$20.46), the easy multiple expansion is already priced in.

LIVE TAPE